Brain and memory supplements: compare the evidence—not the promise
A standards-first hub for memory, focus and cognitive-support formulas. It begins as a research framework, not a one-product ranking.
Products require complete labels, evidence passports, testing records and score coverage before ranking.
Support language is not disease evidence
Memory, attention, focus and cognitive test outcomes are not interchangeable. A study must match the ingredient identity, preparation, amount, population, duration and endpoint before it can inform a product assessment.
This hub does not treat ordinary cognitive-support marketing as evidence for preventing dementia, Alzheimer disease or neurological decline.
What every candidate must disclose
Every ingredient, amount, form, extract and standardization.
Memory, attention, processing speed and focus remain distinct.
Healthy adults, older adults and clinical populations cannot be merged.
Ingredient studies do not become product trials.
Testing requires traceable product, lot, scope and date.
Cost needs a current price and verified serving record.
What the initial Bacopa evidence shows
Some memory signals
A systematic review found signals in selected memory tests across a small set of long-term Bacopa trials, while other cognitive domains were less studied.
Low overall confidence
A broader systematic review found high risk of bias across most included herbal and nutritional studies.
No treatment conclusion
Very-low-certainty evidence did not establish Bacopa as a treatment for Alzheimer disease. Disease claims remain outside this hub.
NeuroVera
Why it is documented
It is a current brain-health offer with an identifiable official page, public seller rules and five publicly named ingredients.
Why it is not ranked
The complete label, all ingredient amounts, exact-product evidence, independent testing and comparable price record are unresolved.